Data of KM curves of phase 3 RCTs in advanced hepatocellular carcinoma (HCC)  

These are 14 FIRST-line trials used in the letter by Bomze et al. in reply to the IMbrave150 publication (Finn 2020, NEJM), sorted chronologically:  
SHARP, Asia-Pacific, SUN1170, BRISK-FL, SEARCH, LIGHT, SARAH, REFLECT, SILIUS, SIRveNIB, SORAMIC, CALGB 80802, CheckMate 459, IMbrave150  

And several SECOND-line trials that were not used in the publication:  
CELESTIAL, REACH2, RESORCE
